GlassScriptPhysician profile
Michael J Aul
NPI 1912303256
$681.78
in general payments reported to CMS, 2019-2025
17 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $195 · 2024: $39.68 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $175.07 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.25 | 2022-2025 | Caplyta |
| Alkermes, INC. | $87.23 | 2024-2025 | Vivitrol |
| Pfizer INC. | $36.24 | 2021 | |
| Nestle Healthcare Nutrition INC. | $35.22 | 2021 | |
| Abbvie INC. | $31.57 | 2022 | |
| Braeburn INC. | $26.24 | 2025 | Brixadi |
| Greenwich Biosciences, INC. | $24.27 | 2021 | |
| Esperion Therapeutics, INC. | $23.39 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.32 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.17 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $18.42 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.79 | 2025 | Rejoyn |
| Sun Pharmaceutical Industries INC. | $16.43 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.81 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $15.25 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Aul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.